In GBM + astrocytoma patients, those with mutated CIC currently on TMZ therapy survived for a median of 1874 days and those patients without CIC mutation survived a median of 602 days (p ≤ 0.001, HR = 2.688) (Supp. This evidence concerns the gene CIC and glioblastoma.